Navigation Links
Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
Date:8/24/2009

BASKING RIDGE, N.J., Aug. 24 /PRNewswire/ -- Regado Biosciences, Inc, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced enrollment of the first patient in the first Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system. The study is a double-blind, randomized, placebo-controlled, single ascending dose study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of RB006 administered subcutaneously, with and without intravenously administered RB007, in healthy adult volunteers. REG1 is a two component system composed of RB006, a specific and direct inhibitor of Factor IXa, and RB007, the specific controlling agent that reverses RB006. To date, this will be the first known use of an aptamer in humans delivered by the subcutaneous route of administration. Recently, Regado successfully completed a phase 2a study of intravenously administered REG1 in stable coronary artery disease patients undergoing elective PCI.

This Phase 1 study will have three primary objectives. First, it will determine the pharmacokinetics, bioavailability and pharmacodynamics of subcutaneous administered RB006. Second, it will determine the safety and tolerability of subcutaneous administered RB006 and third, it will determine the impact of intravenous administered RB007 on the pharmacokinetics, bioavailability and pharmacodynamics in subjects who received subcutaneous administered RB006. The study will enroll a total of 32 subjects.

Dr. Steven L. Zelenkofske, Chief Medical Officer of Regado Biosciences stated, "This is an important milestone in expanding the possible applications of the REG1 system." David J. Mazzo, PhD., President and CEO of Regado Biosciences, added, "The introduction of subcutaneously administered REG1 promises to bring an unprecedented level of individual specific
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Regado Biosciences Expands Medical Advisory Board
2. Regado Biosciences Establishes Medical Advisory Board
3. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
4. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
5. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
6. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
7. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
8. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
9. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
10. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
11. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company ... to manufacture proteins including biosimilar therapeutics, today provided ... the second quarter ended June 30, 2014. ... public offering, we have the capital to continue ... our proprietary protein expression platform," stated Bertrand C. ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... University of the Negev,s Prof. Ron Folman has been named as ... Laser Science and Quantum Optics. The award is presented ... in honor of Willis E. Lamb Jr., who was the 1955 ... physicist and a member of BGU,s Ilse Katz Institute for Nanoscale ...
... Reportlinker.com announces that a new market research report ... Biomarkers - technologies,markets and companies ... This report follows the broad definition of a ... and evaluated as an indicator of normal biological or ...
... NEW YORK, Nov. 9, 2010 NeoStem, Inc. (NYSE Amex: ... biopharmaceutical company with operations in the U.S. and China, today ... M.D., MBA, will be honored tonight at Moves Magazine,s 2010 ... at the Astor Center, 399 Lafayette Street, New York City. ...
Cached Biology Technology:Reportlinker Adds Biomarkers - Technologies, Markets And Companies 2Reportlinker Adds Biomarkers - Technologies, Markets And Companies 3Reportlinker Adds Biomarkers - Technologies, Markets And Companies 4Reportlinker Adds Biomarkers - Technologies, Markets And Companies 5Reportlinker Adds Biomarkers - Technologies, Markets And Companies 6Reportlinker Adds Biomarkers - Technologies, Markets And Companies 7Reportlinker Adds Biomarkers - Technologies, Markets And Companies 8Reportlinker Adds Biomarkers - Technologies, Markets And Companies 9Reportlinker Adds Biomarkers - Technologies, Markets And Companies 10Reportlinker Adds Biomarkers - Technologies, Markets And Companies 11Reportlinker Adds Biomarkers - Technologies, Markets And Companies 12Reportlinker Adds Biomarkers - Technologies, Markets And Companies 13Reportlinker Adds Biomarkers - Technologies, Markets And Companies 14Reportlinker Adds Biomarkers - Technologies, Markets And Companies 15Reportlinker Adds Biomarkers - Technologies, Markets And Companies 16Reportlinker Adds Biomarkers - Technologies, Markets And Companies 17Reportlinker Adds Biomarkers - Technologies, Markets And Companies 18Reportlinker Adds Biomarkers - Technologies, Markets And Companies 19Reportlinker Adds Biomarkers - Technologies, Markets And Companies 20NeoStem Chairman and CEO to be Honored at the Moves 2010 Power Women Awards 2
(Date:8/29/2014)... have made some surprising discoveries about the body,s ... virus (SIV), the team found that specialized cells ... responders to viral invasion and are the source ... interleukin-1 beta (IL-1β). , Though aimed at ... the gut epithelium that provides a barrier to ...
(Date:8/29/2014)... U.S. Ebola researcher from the University of Texas Medical Branch ... of three monoclonal antibodies can completely protect monkeys against a ... infection, at a time when the disease is severe. , ... editorial for Nature discussing advances in Ebola treatment ... are among the most deadly of pathogens, with fatality rates ...
(Date:8/29/2014)... German . ... nitrogen cycle on Earth and in biological wastewater treatment ... depend on nitrite as their source of energy. An ... microbiologist at the University of Vienna, has now shown ... source of energy. The oxidation of hydrogen with oxygen ...
Breaking Biology News(10 mins):The early cost of HIV 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3
... Calif. How much calcium could a hibernating woodchuck,s ... could sequester calcium? More than enough, it turns out, ... heart rhythms such as ventricular tachycardia and ventricular fibrillation ... to a new study of the hibernating animals that ...
... eluded vaccine-makers for thirty years, in part due to ... clinical virologists from the Massachusetts Institute of Technology (MIT) ... a promising strategy for vaccine design using a mathematical ... to quantum physics, as well as in analyses of ...
... restaurant menus might meet federal labeling requirements but don,t do ... meal choices, a new Columbia University School of Nursing (CUSON) ... NP, DNSc, assistant professor of nursing at CUSON, and colleagues, ... Journal of Urban Health . The researchers studied the calorie ...
Cached Biology News:Woodchucks and sudden cardiac death 2Vaccines for HIV: A new design strategy 2Fast-food menu calorie counts legally compliant but not as helpful to consumers as they should be 2Fast-food menu calorie counts legally compliant but not as helpful to consumers as they should be 3
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Mycoplasma and virus tested...
... MagicMark XP Western Protein Standards are ... protein molecular weight estimation directly on ... an IgG binding site, allowing direct ... used to detect your target protein ...
... Clone/PAD: 3F10B10. Immunogen: Synthetic ... region of JAB1 (Jun activation ... Specificity: Specific for the JAB1 ... controls: 293T Jurkat cell lysates). ...
Biology Products: